Rippling raises $450 million, plans $200 million employee equity repurchase. Rippling fetches higher valuation amid tariffs uncertainty.

NEW YORK, March 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alight, Inc. (NYSE: ALIT) between November 12, 2024 and February 18, 2026, both dates inclusive (the "Class Period"), of the important May 15, 2026 lead plaintiff deadline. So what: If you purchased Alight common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

LOS ANGELES--(BUSINESS WIRE)---- $PODD--PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm.

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Kyndryl Holdings, Inc. (NYSE: KD) between August 7, 2024 and February 9, 2026, both dates inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Kyndryl securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SAN DIEGO, March 28, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Trip.com Group Limited (NASDAQ: TCOM) publicly traded securities between April 30, 2024 and January 13, 2026, inclusive (the "Class Period"), have until Saturday, May 11, 2026 to seek appointment as lead plaintiff of the Trip.com class action lawsuit. Captioned De Wilde v.

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also published in Arthritis & Rheumatology INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. These results were presented in a late-breaking presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting and simultaneously published in Arthritis & Rheumatology.

Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.

LOS ANGELES--(BUSINESS WIRE)---- $PRTH--PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm.